Drugs / GC3107
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03363178 | Dec 2017 → Mar 2018 | tuberculosis | Green Cross Corporation | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03947138 | Aug 2019 → Jun 2022 | tuberculosis | Green Cross Corporation | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC3107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03947138 ↗ |
| Known as | BCG Vaccine | “Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally.” NCT03363178 ↗1“A Study of GC3107(BCG Vaccine) in Healthy Infants” NCT03947138 ↗ |